Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: A pooled analysis from three randomized-controlled clinical trials

American Journal of Transplantation

Volumn 13, Issue 5, 2013, Pages 1253-1261

  Bouamar, R ^a   Shuker, N ^a   Hesselink, D A ^a   Weimar, W ^a   Ekberg, H ^b   Kaplan, B ^c   Bernasconi, C ^d   Van Gelder, T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d Limites Medical Research Ltd   (Switzerland)

Author keywords

Biopsy proven acute rejection; pharmacodynamics; tacrolimus concentration; therapeutic drug monitoring; transplantation

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CORRELATIONAL STUDY; DELAYED GRAFT FUNCTION; DOSE RESPONSE; FEMALE; HLA SYSTEM; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT DURATION;

ACUTE DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; TACROLIMUS; TIME FACTORS;

EID: 84876946722     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12191     Document Type: Article

References (21)

1. Recipients OPaTNaSRoT. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation (ed.). Am J Transplant 2012 (Suppl 1); 13: 11-46.
2. Borobia AM, Romero I, Jimenez C, et al. Trough tacrolimus concentrations in the first week after kidney transplantation are related to acute rejection. Ther Drug Monit 2009; 31: 436-442.
3. Staatz C, Taylor P, Tett S,. Low tacrolimus concentrations and increased risk of early acute rejection in adult renal transplantation. Nephrol Dial Transplant 2001; 16: 1905-1909.
4. Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth CG,. Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 1999; 48: 445-448.
5. Kershner RP, Fitzsimmons WE,. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996; 62: 920-926.
6. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296-298.
7. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ,. An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: A report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996; 62: 900-905.
8. Nashan B, Saliba F, Durand F, et al. Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. Liver Transpl 2009; 15: 136-147.
9. Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK,. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: A systematic review and meta-analysis. Am J Transplant 2012; 12: 2797-814.
10. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043-1051.
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575.
12. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept trial. Am J Transplant 2009; 9: 1607-1619.
13. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
14. van Gelder T, Tedesco Silva H, de Fijter JW, et al. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation 2010; 89: 595-599.
15. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol 2010; 5: 341-358.
16. Capone D, Tarantino G, Kadilli I, et al. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine. Nephrol Dial Transplant 2011; 26: 3019-3025.
17. Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P,. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: Preliminary results of a prospective study. Transpl Int 2012; 25: 41-47.
18. Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y,. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434-447.
19. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009; 31: 139-152.
20. Barraclough KA, Staatz CE, Johnson DW, et al. Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. Transpl Int 2012; 25: 1182-1193.
21. LaRosa DF, Rahman AH, Turka LA,. The innate immune system in allograft rejection and tolerance. J Immunol 2007; 178: 7503-7509.